Takeda Pharmaceutical (TAK) Interest Expenses (2017 - 2026)

Takeda Pharmaceutical's Interest Expenses history runs 10 years deep, the most recent figure standing at -$278.3 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 59.29% year-over-year to -$278.3 million; the TTM figure through Mar 2026 stood at -$3.2 billion (down 34.29% YoY), while the FY2026 annual figure was -$2.4 billion, down 72.25% from the prior year.
• Interest Expenses was -$278.3 million for Q1 2026 at Takeda Pharmaceutical, up from -$324.9 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $2.7 billion in Q1 2022 to a low of -$2.1 billion in Q3 2025.
• Historically, Interest Expenses has averaged -$197.2 million across 5 years, with a median of -$414.3 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses surged 739.32% in 2024, then tumbled 125.81% in 2025.
• A 5-year view of Interest Expenses shows it stood at -$564.5 million in 2022, then soared by 50.62% to -$278.7 million in 2023, then retreated by 11.86% to -$311.8 million in 2024, then declined by 4.2% to -$324.9 million in 2025, then increased by 14.33% to -$278.3 million in 2026.
• The last three Interest Expenses figures came in at -$278.3 million (Q1 2026), -$324.9 million (Q4 2025), and -$2.1 billion (Q3 2025), per Business Quant data.